about
OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in Acinetobacter baumanniiAcinetobacter dijkshoorniae sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex mainly recovered from clinical samples in different countries.RIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cellsHead-to-Head Comparison of Two Multi-Locus Sequence Typing (MLST) Schemes for Characterization of Acinetobacter baumannii Outbreak and Sporadic IsolatesAssociation between β-lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of Acinetobacter baumannii isolatesIn vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens.The Asp20-to-Asn Substitution in the Response Regulator AdeR Leads to Enhanced Efflux Activity of AdeB in Acinetobacter baumannii.Development and evaluation of a core genome multilocus typing scheme for whole-genome sequence-based typing of Acinetobacter baumanniiCharacterization of blaOXA-143 variants in Acinetobacter baumannii and Acinetobacter pittii.Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolatesA Nosocomial Outbreak of Extensively Drug Resistant (XDR) Acinetobacter baumannii Isolates Containing blaOXA-237 Encoded on a Plasmid.Outbreak of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: a multi-level strategic management approach.Emergence of different Acinetobacter baumannii clones in a Croatian hospital and correlation with antibiotic susceptibility.In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.Draft Genome Sequences of 11 Clinical Isolates of Acinetobacter baumannii.First Report of the Carbapenemase Gene blaOXA-499 in Acinetobacter pittii.Effects of Saline, an Ambient Acidic Environment, and Sodium Salicylate on OXA-Mediated Carbapenem Resistance in Acinetobacter baumannii.Prevalence of eight resistance-nodulation-division efflux pump genes in epidemiologically characterized Acinetobacter baumannii of worldwide origin.gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3.Molecular epidemiology of Acinetobacter baumannii bloodstream isolates obtained in the United States from 1995 to 2004 using rep-PCR and multilocus sequence typing.Amino acid alterations in fibronectin binding protein A (FnBPA) and bacterial genotype are associated with cardiac device related infection in Staphylococcus aureus bacteraemia.In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.Characterization of RarA, a novel AraC family multidrug resistance regulator in Klebsiella pneumoniae.High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.Surface-associated motility, a common trait of clinical isolates of Acinetobacter baumannii, depends on 1,3-diaminopropane.Differential expression of ccrA in methicillin-resistant Staphylococcus aureus strains carrying staphylococcal cassette chromosome mec type II and IVa elements.In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii.Relatedness of wildlife and livestock avian isolates of the nosocomial pathogen Acinetobacter baumannii to lineages spread in hospitals worldwide.Global spread of carbapenem-resistant Acinetobacter baumannii.Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009).Detection of pan drug-resistant Acinetobacter baumannii in Germany.Nosocomial spread of OXA-23 and OXA-58 beta-lactamase-producing Acinetobacter baumannii in a Bulgarian hospital.Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital.Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa.Evidence of cross-resistance between ciprofloxacin and non-fluoroquinolones in European Gram-negative clinical isolates.Detection of intrinsic blaOXA-51-like by multiplex PCR on its own is not reliable for the identification of Acinetobacter baumannii.Conversion of OXA-66 into OXA-82 in clinical Acinetobacter baumannii isolates and association with altered carbapenem susceptibility.Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii.
P50
Q28286208-B9FF6C96-DB38-4220-8549-C7DDE25944F7Q31115617-07076490-3A7B-4AFB-B6DC-2D9B98CDEDA6Q34709924-17A8186C-4BE8-4517-9A38-CA538A54EC96Q35987449-8A44BAF1-FE40-446B-B2A7-D5C45D459ABBQ36022817-86D2317D-AC1A-497D-8CA0-CD57D9B322ECQ37733474-84D3A9E2-EB71-46F9-9B5D-5BDF468C7FC1Q38270541-931D5FC7-33AB-4DAC-92DF-806FA153E274Q38343255-BA8D021C-3E9A-48DF-97DA-44A8266F8168Q38367772-A64F243E-EC03-4301-A639-40834E6CF65BQ38736293-9BC4E0F2-0B16-4CB1-983B-BFA7966DAC7AQ38848691-12830AFF-DF57-4078-AD28-722D3018810FQ39895046-B31090CB-F87D-4CCD-9581-6DDD5887495CQ40046806-DC44AD97-C8AF-4451-A00C-52FE8F1FA2E4Q40096761-E7359D91-3156-412F-8140-C61E03E3F2A1Q40112121-BF5B25B2-FE82-4D7F-82B6-B798E48EEC57Q40135682-0D785A60-E9C4-4C71-A6C5-B407BD1D1D8FQ40189053-06E12EE9-FA8B-45F2-B31E-ED00A312CF20Q40306186-A75258E7-2CC4-4D54-B884-E74C648A0C20Q40746017-9ABE0ADC-BEA7-460F-A340-018E82D85EBDQ41334837-041D4C2D-A089-4FCA-9143-78E20E548556Q41429609-AA56CBBA-13A2-4744-9A67-505A91CAA389Q41580863-4A067843-17AA-4DD4-8D48-BAB0192AEE96Q41729521-8705F15B-E1E7-44EE-AC8B-3DBC7AB01CA8Q41762176-B3880057-8EE8-41A1-ABDC-2E1CDF1C5E81Q41858474-853771FC-CA9E-4824-981D-BC9468714033Q41992993-011CFB28-83B8-4EDA-9EB9-0DAFB52B2D7FQ42013251-536B2B91-0E9C-41CD-8F1B-C20B3F495978Q42586774-D5A1F5A7-8A3F-4132-8417-559305CCA013Q43014539-804C1A69-DDBF-45BB-8F96-16010DEBA972Q43168703-29182772-5264-47A6-97EC-2D73F181E0D2Q43227337-1ADB8C5B-CFAD-474B-B60A-7F5A42E1C796Q43575502-9C0AADD3-70B4-4B84-8253-CC0E00C3886DQ43684132-EF0EE266-6D32-4BA6-86B8-183BED5E9A7DQ43928111-9BF83556-8DF1-425C-A8E6-0E374B58C13AQ43928291-F42B645A-57EE-4229-970F-5D018510340BQ44088923-1E7A8F73-AC3E-4B2F-8D49-5B0A43F09953Q44121073-C7B5D096-10E9-4389-AC1B-ACA9F6E9A553Q44312480-F17803E4-241E-44B2-9B72-AFEA4098C864Q44775210-F7D3B84C-011A-476B-9E56-BC88592E546DQ45050449-7F0AD86C-666C-4CE2-AC04-B31B7DCE07CC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul G Higgins
@ast
Paul G Higgins
@en
Paul G Higgins
@es
Paul G Higgins
@nl
Paul G Higgins
@sl
type
label
Paul G Higgins
@ast
Paul G Higgins
@en
Paul G Higgins
@es
Paul G Higgins
@nl
Paul G Higgins
@sl
prefLabel
Paul G Higgins
@ast
Paul G Higgins
@en
Paul G Higgins
@es
Paul G Higgins
@nl
Paul G Higgins
@sl
P1053
B-6708-2011
P106
P21
P31
P3829
P496
0000-0001-8677-9454